Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28494149 | 0.91 | PKM (0.36) | GAACA1CA2CA12CA3 | |
| SCHEMBL14779904 | 0.87 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL12212901 | 0.84 | CA2 (0.41) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL28738302 | 0.81 | NR1H2 (0.31) | KEAP1NFE2L2PKM | |
| SCHEMBL10711576 | 0.81 | CA2 (0.45) | GAACA1CA2CA12CA9 | |
| SCHEMBL10799130 | 0.81 | ALDH1A1 (0.48) | GAACA1CA2CA12CA3 | |
| SCHEMBL28494151 | 0.81 | LMNA (0.46) | SMN1; SMN2ALDH1A1HTTLMNAMAPT | |
| SCHEMBL8633771 | 0.81 | MEN1 (0.43) | CA1CA2ALDH1A1MMP1MMP2 | |
| SCHEMBL10793501 | 0.81 | ENPP2 (0.50) | GAACA1CA2CA12CA7 | |
| SCHEMBL28755044 | 0.80 | KEAP1 (0.44) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024250071-A1 | BI-ENZYMATIC BIOSENSOR | THE UNIVERSITY OF SYDNEY (AU) | 2024-12-12 | — | — | WO | claimed |
| CN-115668459-A | Surface treatment method for semiconductor substrate and surface treatment agent composition | 中央硝子株式会社 | 2023-01-31 | — | — | CN | claimed |
| WO-2023283188-A1 | BEDDING SYSTEMS BASED ON LOCALIZED CLIMATE CONTROL, AND RELATED METHODS | Soft-Tex International, Inc. (US) | 2023-01-12 | — | — | WO | claimed |
| US-9670299-B2 | Polymers functionalized with nitroso compounds | BRIDGESTONE CORPORATION (JP) | 2017-06-06 | — | — | US | claimed |
| US-20160032030-A1 | POLYMERS FUNCTIONALIZED WITH NITROSO COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2016-02-04 | — | — | US | claimed |
| EP-2031031-B1 | Use of a latent acid for improving adhesion | SIKA TECHNOLOGY AG (CH) | 2011-07-13 | — | — | EP | claimed |
| EP-0615163-B1 | Positive resist material using particular onium salts | SHINETSU CHEMICAL CO (JP) | 1999-12-29 | — | — | EP | claimed |
| EP-0143323-B1 | PROCESS FOR AN ANTHRACYCLINE DERIVATIVE, AND AN ANTHRACYCLINONE DERIVATIVE USEFUL FOR THE PROCESS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1988-10-26 | — | — | EP | claimed |
| US-4564674-A | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-01-14 | — | — | US | claimed |
| EP-0143323-A2 | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-06-05 | — | — | EP | claimed |
| EP-4720678-A1 | SURVIVIN AS A BIOMARKER FOR PREDICTING THE RESPONSIVENESS OF CANCER TREATMENT | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712169-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | SK On Co., Ltd. (KR) | 2026-03-18 | — | — | EP | disclosed |
| US-20260074285-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | SK ON CO LTD (KR) | 2026-03-12 | — | — | US | disclosed |
| US-12502126-B2 | Wearable device | Price Dawn (GB) | 2025-12-23 | — | — | US | disclosed |
| US-20250357540-A1 | Electrolyte for Lithium Secondary Battery and Lithium Secondary Battery Including the Same | SK ON CO LTD (KR) | 2025-11-20 | — | — | US | disclosed |
| EP-0154822-B1 | ANAEROBICALLY CURABLE ADHESIVE OR MASTIC COMPOSITION | Teroson GmbH (DE) | 1987-05-20 | — | — | EP | disclosed |
| US-4565883-A | Cyanoacrylate adhesive composition | TEROSON GMBH (DE) | 1986-01-21 | — | — | US | disclosed |
| US-4564674-A | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0165509-A1 | Process for the improvement of the solubility of certain organic compounds which are sparingly soluble in inert solvents by silylation with trialkylsilylcyanide | BAYER AG (DE) | 1985-12-27 | — | — | EP | disclosed |
| EP-0143323-A2 | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260074285-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | CLCN2, KCNN2, HCN2 | GAA 3056/4885CA1 136/4885CA2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.